/biz/ - Business & Finance

https://abc30.com/health/stem-cells-extend-stroke-treatment-window/3024501/

"PORTLAND, Ore. (KFSN) -- Nearly 800,000 people have strokes every year in America. The best treatment, tPA (tissue plasminogen activator), has to be given within three hours, and doctors estimate only five percent of patients can make that window. A new treatment that is now in clinical trial could give patients precious additional time.

Sharon Thomas is back at work like nothing was ever wrong. But four years ago, she had a stroke.

"At that time, I couldn't read, write, swallow or speak," Thomas told Ivanhoe.

She was helicoptered to OHSU and the care of Wayne Clark, MD, Director, Oregon Stroke Center, Oregon Health & Science University. He asked if she wanted to be part of a trial for a stem cell treatment that might help her recover. (Read Full Interview)

"What this does, the stem cells are from very, very young cells, and they bathe the brain in this environment that makes it act like it's young again," explained Dr. Clark.

The stem cells also turn off the inflammatory response sent by the spleen to the brain. The bone marrow-derived stem cells come from a donor and are multiplied in a lab.

Doctor Clark continued, "It can be easily stored in a refrigerator, and mixed up quickly, and given by IV. So no specialized facilities will have to be ... and a 36 hour window, so it could really allow a lot of patients to potentially benefit."

Sharon made a significant recovery, like 70 percent of patients in the multistem trial. She credits it with giving her an edge.

Thomas said, "Every day it got better, and my mantra was, 'every day is a good day,' because I'm still here, I'm still improving."

And she hopes more stroke patients have access to MultiStem."

Check this video out this is insane:
https://vimeo.com/259418414

Phoneposting, so keeping it short.
AMDA - Amedica
Another stock you should look into to get the bottom since they own the future of next gen implants.

We going to make it

>>10820924
I think so, it appears this will be the standard of care for stroke following approval.

>>10820239
Are you just shilling your bags? Gah, I hope not!

>>10820239
This was a PnD back it the day. How heavy are those bags bud?

>>10822376
I'm holding these 'bags' for a minimum of 3 more years. I don't expect significant gains for about 1.5-2 years

>>10822567
Can you elaborate?

>>10821592
i know this girl i fucked her once as i remember

>>10820239
Shill me anon. How do you come up with a $150-$250 valuation?
What does their balance sheet look like?
What's the timeframe to be out of stage 3?

This is some vintage biz, peddling the pennies, ahhh... the good ol days SIIIIIIIIIIIIIIIP

>>10824009
Beat me to it

T. healthcarefag

How the hell do you buy stocks online

>>10820239
Don’t mean to hijack, but what about US stem cells? I saw a tip on here about a year ago and been considering ever since

>>10820239
wow shit why do I know about this now ?
My dad had a stroke and was in a vegetative state this could have helped him.

>>10824861
this is very new medicine. How long ago was his stroke?

>>10820239
>>10820249
>>10820284
I've been burned by BioPharma way too many times to get into this shit. Do you have any published scientific papers on their trail runs, or anything that isn't just standard sensationalized media garbage?

>>10824861
Its not released for consumers yet, it's an experimental medicine undergoing FDA trials. If you have a stroke and happen to be lucky enough to go to a hospital where they're doing the trials, then you have a 50/50 chance of receiving MultiStem or the placebo at that point.

So far in phase 1 and 2 tests the MultiStem control group has shown considerable recovery vs the placebo group. It works.

>>10824976
http://journals.sagepub.com/doi/abs/10.1111/ijs.12065

>>10824009
It appears Athersys will go ahead in the US alone, without a partner and ATHX will take 100% royalties. The below numbers are calculated in a scenario where they take 80% profit with a partner:

Per CDC, new strokes per year in the US 610,000- 87% ischemic= 530,000, 25% of which to be treated with MultiStem equalling 132,000 doses at a very conservative $25,000 per treatment (more than enough wiggle room for insurance negotiations/medicare/etc), this comes to $3,312,000,000 gross (well below the William Blair top estimate)

At 80% royalty to ATHX, $2,650,000,000 top line after tax profit margin 60%, $1,590,000,000 net P/E 20, $31,800,000,000 market cap shares out 300,000,000 +/-

PPS = $106.00 (80% US with a partner, doesnt include profits from foreign sales and royalties)

>>10824021
Galaxy resources bro

>>10824021
*sip*
Now /asx/... that was a REAL general.

>>10825378
>Conclusions and future direction
>If MultiStem is safe and there is a signal of efficacy, a late stage phase IIb-III trial is planned.
Wow it's fucking nothing. The paper says nothing more than "we are doing a trial"

>>10821592
I'd give her a few strokes

>>10820239
If I stick it in my dick, will it grow? Really all I'm concerned about here.

>>10825696
>t.brainlet

>>10825696
This is an older paper, MultiStem is currently in STAGE III FDA Testing.

ETA about 1.5 - 2 years to commercialization.

Pipeline status in pic related and in this URL
http://www.athersys.com/clinical-programs/overview

>>10825696
>>10826066
Also has FAST TRACK designation from the FDA for the Stage III clinical trials. This is the real deal.

>>10825734
these are the questions

>>10824848
Looks like they mostly focus on degenerative diseases (Alzheimers, etc)
Multistem is designed specifically for stroke and may also help with organ failure that causes cell death like heart failure, or aid in recovery from massive injuries like TBI. This will be an "ER STOCK ROOM" treatment, rather than something that's given out during long term specialist treatment like what US Stem Cells is working on. MultiStem is a money maker, they should be producing hundreds of thousands, even millions of doses worldwide.

>>10825398
Expanding to include the other territories could drive the price into the high hundreds.

But even at the worst case (assuming approval in all territories) the upside is enormous.

SP = $204 Based on:

Japan (62k strokes, $25,000/dose, 10% royalty), USA (132k strokes, $25,000/dose, 100% royalty), Europe (283k strokes, $25,000/dose, 10% royalty), Canada (45k strokes, $25,000/dose, 100% royalty) Expenses ($25M R+D, $8M Admin) Tax (40%) Shares (310,000,000) P/E (20)

>>10826066
Do you have any papers detailing the results of the phase II trial?

>>10826421
http://www.athersys.com/news-releases/news-release-details/one-year-results-phase-2-stroke-study-multistemr-cell-therapy

Pic related is solely those with "Excellent Outcome" in Phase 2. Significant proportion over placebo. EG: Full blown recovery as if nothing occurred, like in the news stories.

"We are particularly excited by the one-year follow-up results because they show that MultiStem treatment can significantly increase the number of patients who have an Excellent Outcome, meaning complete or nearly full recovery, over the standard of care when considering all subjects in the trial," commented Dr. Gil Van Bokkelen, Chairman & CEO at Athersys. "The one-year data continues to confirm that MultiStem treatment is well tolerated and is associated with continued improvement of other measures of function through one year. As we saw in the 90-day interim analysis results announced last April, patients who received MultiStem treatment within 36 hours of the stroke did substantially better than placebo patients and later treatment MultiStem subjects. As a result, we will continue to focus our ongoing clinical development on treatment within 36 hours of the stroke."

Data highlights from the 365-day follow-up data analysis include:

MultiStem treatment continued to be well tolerated through 365 days;
Among all subjects who received MultiStem treatment (n=65), 23.1% of patients achieved an Excellent Outcome at 365 days, compared to 8.2% of patients who received placebo (n=61), and the 14.9% difference was statistically significant (p=0.02) and compared favorably to the 8.8% difference at 90 days;
Among patients who received MultiStem treatment within 36 hours following the stroke, 29.0% achieved Excellent Outcomes (n=31), and compared to all placebo subjects (n=61), the 20.8% difference was significant (p &#60 0.01) and also greater than the 9.5% difference at 90 days;

>>10826421
>>10826620
Substantial improvements were also observed in the Barthel Index, which is the clinical scale used to assess the ability of patients to live independently. Among all subjects (65 MultiStem, 61 placebo), 61.5% of MultiStem patients had an excellent outcome in the Barthel Index (≥95), compared to 44.3% of placebo patients (p=0.05); furthermore, 67.7% of the subset of MultiStem patients who had treatment within 36 hours (n=31) achieved an excellent Barthel outcome, representing a 23.4% difference with the incidence for all placebo patients (p=0.03); and
Among MultiStem patients who did not achieve an Excellent Outcome at 365 days, there appears to be meaningful benefit from the treatment relative to standard of care, with reductions in average initial hospitalization days, mortality, life threatening adverse events and infections. For example, comparing all such MultiStem and placebo subjects, MultiStem-treated patients had 1.6 fewer average hospitalization days, and an 11% lower proportion of patients with death or life threatening adverse events. In addition, when comparing subjects receiving early treatment with MultiStem against all placebo subjects, MultiStem patients had an average of 2.9 fewer hospitalization days, and an 11.4% lower incidence of death or life threatening adverse events. Further, such MultiStem patients appear to have better functional improvement than these placebo patients over one year, as evidenced by a higher proportion of excellent Barthel Index outcomes (≥95), 50% for MultiStem subjects (and 55% for early treatment MultiStem), compared to 39% for placebo subjects.

>>10826620
>>10826630
Thanks for the info, I'll have a serious look into this.

>>10826421
https://clinicaltrials.gov/ct2/show/NCT01436487

probably made up chink shit, your telling me that some "magic medicine" can magically heal strokes

fuck off ching chong

This shit can be denied in phase 3 and crash 90%. I'll do more research

>>10826675
A significant portion of failed Phase III studies that are denied are due to safety concerns, there haven't been any safety concerns raised from injecting this stem cell treatment.

The rest that fail are due to the treatment failing to show efficacy. Based on what we've seen in Phase 1 and 2, for 18 hour and 36 hour baselines for giving MultiStem after a stroke it seems like its in the bag. There'd have to be a gigantic statistical anomaly for the results to be significantly different enough in Phase 3 to shut it down.

If a company found a really good stem cell research, they would be hiding it, not talking about it----not asking losers on a Chinese cartoon forum to buy their stock.

These threads randomly appeared and have been made daily for a few days now, this is a crypto board when you shill a stock it really stands out and you look stupid & waste your time. Try reddit instead.

>>10826704
A company would be hiding their FDA trials and not raising money to fund trials and production by selling stock? Yeah, that makes a lot of sense to me.

>>10826704
>this is a crypto board
Also, this is /biz/, newfag.

>>10826704
kys

BTW this today exceeded the 50-day MA, closing at 2.01 today. Not a pink sheet penny stock